Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status Prescription
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 60505-3250; 53873-075; 53873-073; 55773-0589; 49702-204; 49702-203; 50742-623; 65015-701; 68180-603; 50742-624; 65862-259; 53873-074; 54838-566; 31722-752; 64380-711; 49702-205; 31722-001; 70159-001; 52482-003; 64380-710; 31722-753; 68554-0043; 65862-026; 33342-001; 69097-167; 70518-3267; 57237-274; 65015-756; 70518-2067; 70518-2070; 67835-0017; 0173-0662; 53104-7538; 60687-362; 0173-0663; 60505-3252; 53104-7677; 65862-025; 68180-602; 65862-055; 68554-0016; 66993-478; 31722-754; 65862-577; 69097-166; 42385-714; 33342-002; 60505-3251; 60429-354; 60429-353; 0904-6583
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperamylasaemia14.11.01.003--Not Available
Breath sounds abnormal13.15.01.0080.004638%Not Available
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.004235%Not Available
Viral skin infection23.09.03.004; 11.05.04.004--Not Available
Bone marrow failure01.03.03.0050.004638%
Hyperpathia17.02.07.015--Not Available
Treatment failure08.06.01.0170.018753%Not Available
Liver injury12.01.02.003; 09.01.07.0220.004638%Not Available
Low birth weight baby18.04.02.0030.004638%Not Available
Mucosal pigmentation08.01.06.006--Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.008--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.016--
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.002420%Not Available
Sensitisation10.02.01.012; 08.01.05.009--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.025508%Not Available
Hepatic cancer16.07.02.004; 09.04.02.0080.001210%Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.007259%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.001815%
Immune-mediated adverse reaction10.02.01.0440.004638%Not Available
Liver function test increased13.03.01.044--Not Available
Persistent depressive disorder19.15.01.006--Not Available
Birth mark23.05.01.014; 03.05.01.0160.006049%Not Available
Congenital umbilical hernia07.16.03.003; 03.04.07.0060.016233%Not Available
Dextrocardia03.07.12.001; 02.08.03.0010.004638%Not Available
Double outlet right ventricle03.07.08.006; 02.08.03.0020.009276%Not Available
Maternal drugs affecting foetus18.03.03.009; 12.03.03.0060.025508%Not Available
Meningitis tuberculous17.06.10.005; 11.04.01.0120.001210%Not Available
Mitral valve stenosis02.07.01.0090.004638%Not Available
Neonatal asphyxia22.11.02.006; 18.04.15.0050.009276%Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages